Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indevus Adds Senior VP-Clinical Development From Praecis

This article was originally published in The Pink Sheet Daily

Executive Summary

James Shipley, MD, will support medical affairs and post-marketing safety surveillance for the overactive bladder agent Sanctura. He will also evaluate development strategies for pipeline products.

You may also be interested in...



Indevus To Price Sanctura At 10% Discount To Pfizer Detrol LA

A daily dose of Sanctura – two 20 mg tablets – will carry an average wholesale price of $2.98. Retail pharmacies will begin receiving initial shipments of the incontinence agent over the next week, Indevus said.

Plenaxis Medicare National Coverage Decision Needed To Cement Prescriber Base, Praecis Says

Providers are signing up to prescribe the prostate cancer drug through Praecis’ closed distribution system but waiting for a clear coverage determination before delivering the drug to patients, the company says. Praecis is proposing coverage for listed indications and clinical trials.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Topics

UsernamePublicRestriction

Register

PS060748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel